Patents Assigned to ONCORUS, INC.
  • COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20240173267
    Abstract: The present disclosure includes, among other things, lipids, compositions, and methods useful for delivering a polynucleotide or oligonucleotide, e.g., viral genome.
    Type: Application
    Filed: January 6, 2022
    Publication date: May 30, 2024
    Applicant: Oncorus, Inc.
    Inventors: Jessica Deterling, Sean Essex, Lorena Lerner, Qi-Ying Hu, Christophe Quéva
  • Oncolytic viral vectors and uses thereof
    Patent number: 11612625
    Abstract: Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 28, 2023
    Assignee: Oncorus, Inc.
    Inventors: Mitchell H. Finer, Lorena Lerner, Christophe Quéva, Edward Kennedy
  • Oncolytic viral vectors and uses thereof
    Patent number: 11452750
    Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: September 27, 2022
    Assignee: Oncorus, Inc.
    Inventors: Kenneth P. Greenberg, Mitchell H. Finer
  • Oncolytic viral delivery of therapeutic polypeptides
    Patent number: 11078280
    Abstract: Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: August 3, 2021
    Assignee: Oncorus, Inc.
    Inventors: Luke Evnin, Mitchell H. Finer
  • Oncolytic viral delivery of therapeutic polypeptides
    Patent number: 10604574
    Abstract: Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: March 31, 2020
    Assignee: ONCORUS, INC.
    Inventor: Luke Evnin
  • Oncolytic viral vectors and uses thereof
    Patent number: 10391132
    Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: August 27, 2019
    Assignee: ONCORUS, INC.
    Inventors: Kenneth P. Greenberg, Mitchell H. Finer